m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01131)
Name
Arsenite
Synonyms
13768-07-5; AC1L2NJ5; Arsenenous acid; Arsenite (ion)
    Click to Show/Hide
Status
Investigative
Structure
3D MOL
2D MOL
Formula
AsHO2
InChI
1S/AsHO2/c2-1-3/h(H,2,3)
InChIKey
XHTRYVMKFMUJLU-UHFFFAOYSA-N
PubChem CID
24577
VARIDT Drug ID
DR00312
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Glucose transporter type 1 (SLC2A1)
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Glucose transporter type 1 (SLC2A1) is a therapeutic target for Arsenite. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Arsenite through regulating the expression of Glucose transporter type 1 (SLC2A1). [1], [2]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Glucose transporter type 1 (SLC2A1) is a therapeutic target for Arsenite. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Arsenite through regulating the expression of Glucose transporter type 1 (SLC2A1). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Glucose transporter type 1 (SLC2A1) is a therapeutic target for Arsenite. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Arsenite through regulating the expression of Glucose transporter type 1 (SLC2A1). [1], [2]
References
Ref 1 m(6)A-dependent glycolysis enhances colorectal cancer progression. Mol Cancer. 2020 Apr 3;19(1):72. doi: 10.1186/s12943-020-01190-w.
Ref 2 Mammalian glucose permease GLUT1 facilitates transport of arsenic trioxide and methylarsonous acid. Biochem Biophys Res Commun. 2006 Dec 15;351(2):424-30. doi: 10.1016/j.bbrc.2006.10.054. Epub 2006 Oct 17.